Commonwealth Equity Services’s Prelude Therapeutics PRLD Stock Holding History

Commonwealth Equity Services’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-15,307	Closed	-$92K	–	3840
2022 Q4	$92K	Sell	15,307 -560	-4%	-$3.59K	﹤0.01%	3429
2022 Q3	$104K	Sell	15,867 -750	-5%	-$5.06K	﹤0.01%	3365
2022 Q2	$86K	Sell	16,617 -3,850	-19%	-$19.6K	﹤0.01%	3402
2022 Q1	$141K	Sell	20,467 -2,365	-10%	-$21.6K	﹤0.01%	3417
2021 Q4	$284K	Buy	22,832 +9,350	+69%	+$152K	﹤0.01%	3021
2021 Q3	$421K	Buy	13,482 +2,555	+23%	+$82.7K	﹤0.01%	2605
2021 Q2	$312K	Buy	+10,927	New	+$389K	﹤0.01%	2858

Other funds holding PRLD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Commonwealth Equity Services's PRLD Position: Q1 2023 in Review

Commonwealth Equity Services sold out of Prelude Therapeutics (PRLD) in Q1 2023, closing a stake of 15,307 shares — an estimated $92K sold.

Commonwealth Equity Services first reported a position in PRLD in Q2 2021 and held it in 7 quarters. The position peaked at $421K in Q3 2021. 54 funds tracked by Wall St. Rank hold PRLD as of Q1 2023.

Commonwealth Equity Services reported no remaining Prelude Therapeutics position as of Q1 2023 after selling out during the quarter.
Commonwealth Equity Services sold 15,307 Prelude Therapeutics shares in Q1 2023, an estimated $92K.
Commonwealth Equity Services first reported a position in Prelude Therapeutics in Q2 2021 and held it in 7 quarters.
Commonwealth Equity Services's Prelude Therapeutics position peaked at $421K in Q3 2021.
54 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2023.

Based on Commonwealth Equity Services's 13F filing for Q1 2023, filed 11 May 2023.